Skip to main menu Skip to main content Skip to footer


At Neurotech, we want to understand your journey, experiences, and unique needs. 

We are committed to ongoing collaboration with the MacTel patient community and physicians involved in their care. We know that by engaging with and learning from you, we can better serve patients and their caregivers. You inspire us to learn as much as we can to continue advancing treatments that will improve the quality of life for those with chronic retinal disease.

Please visit for more information about MacTel.

Please review these Frequently Asked Questions for the most up to date information about our work. If you have additional questions, please contact us at

The application for NT-501 for the treatment of Macular Telangiectasia type 2 (MacTel) is currently under priority review by the FDA.  The application, filed earlier this year, was deemed sufficiently complete by the agency and a PDUFA date has been set as December 17, 2024 (the goal date for the FDA to complete their review and render a decision).  Neurotech will continue to provide updates as they are available. 

If approved, NT-501, will be the only approved treatment for MacTel in the United States. We will be working proactively to help ensure access to patients.

The price of NT-501 has not yet been determined; it represents a novel potential therapy, and we are in discussions with insurance companies and other stakeholders regarding the value of this product to patient care. Regardless of the price of the product, we are creating a robust patient service program to help ensure that individuals who are prescribed the product will have access to it.

NT-501 is intended for individuals who have been diagnosed with MacTel. The product label will determine eligibility. Decisions about who is eligible for our product will be up to clinicians, individual patients, and insurers. All products approved by the FDA have a recommended population for whom the drug / device is intended. We encourage anyone who is interested in learning more about NT-501 to speak to their physician, as all healthcare decisions should be made by you and your health care team.

We are not able to provide you with individual medical advice. We recommend that you speak to your physician about your interest in NT-501.

For past or current trial participants, we recommend that you speak with your physician at the clinical trial site.

Community Resources

Prevent Blindness

National Organization for Rare Disorders (NORD)

American Academy of Ophthalmology

Foundation Fighting Blindness